USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Zynaxis, Inc.
Address:
371 PHOENIXVILLE PIKE
MALVERN, PA 19355
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $300,000.00 5
SBIR Phase II $1,177,645.00 2

Award List:

CELL TRACKING USING A NOVEL LINKER TECHNOLOGY

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

LOW-COST HELPER-CELL MONITORING USING NOVEL CELL LINKERS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Katharine Muirhead
Abstract:
Quantitation of cd4(+) lymphocyte levels by flow cytometry is the most common measure of progression of hiv-infected individuals toward frank aids. this project will couple novel lipophilic cell linkers with existing magnetic bead-based cell separation techniques to produce an inexpensive… More

CELL TRACKING USING A NOVEL LINKER TECHNOLOGY

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$491,477.00
Agency:
HHS
Principal Investigator:
Abstract:
Zynaxis cell science, inc., has developed fluorescent cell-tracking molecules that bind cell membranes via a high-affinity lipophilic linker without affecting viability or growth. radionuclide-carrying analogs would allow clinical use of this novel technology with many cell types to follow migration… More

ZYNPEPTIDES AS MODULATORS OF RESPONSES TO BIOMATERIALS

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Kopia, Gregory A , Principal Investigator
Abstract:
Intravascular stents are spring-like devices which are placed in atherosclerotic human coronary and iliac arteries to keep them from collapsing after balloon angioplasty. a necessary adjunct to stent implantation is systemic antiplatelet and anticoagulant therapy to prevent acute thrombosis with the… More

Zyn-Linkertm/Heparin Conjugate to Prevent Restenosis

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Gregory A Kopia
Abstract:
N/a

Zyn-Linkertm/Heparin Conjugate to Prevent Restenosis

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$686,168.00
Agency:
HHS
Principal Investigator:
Gregory A Kopia
Abstract:
Risk assessment for chronic heart disease (chd) uses indirect estimates of ldl cholesterol from total cholesterol, hdl and vldl estimates. no clinical assay exists to quantitate ldl directly from serum. we will use a model ldl determination assay using pkh26-zyn-linker labelled ldl particles (ldls)… More

SYN LINKER/PACLITAXEL CONJUGATES TO PREVENT RESTENOSIS

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a